Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday

Fulcrum Therapeutics (NASDAQ:FULC) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Fulcrum Therapeutics Stock Down 2.1%

Shares of NASDAQ FULC opened at $10.63 on Tuesday. The company has a market capitalization of $575.30 million, a PE ratio of -9.01 and a beta of 3.19. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $15.74. The firm has a fifty day simple moving average of $11.11 and a 200 day simple moving average of $9.32.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares in the company, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 4,205,139 shares of company stock worth $58,711,943. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Siren L.L.C. bought a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $22,054,000. GSK plc bought a new position in Fulcrum Therapeutics during the 4th quarter valued at $20,196,000. Adage Capital Partners GP L.L.C. boosted its holdings in Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after acquiring an additional 1,589,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Fulcrum Therapeutics during the 2nd quarter worth $9,207,000. Finally, Invesco Ltd. grew its stake in shares of Fulcrum Therapeutics by 448.4% in the 2nd quarter. Invesco Ltd. now owns 470,333 shares of the company’s stock worth $3,236,000 after acquiring an additional 384,566 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on FULC. JPMorgan Chase & Co. started coverage on Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective on the stock. Stifel Nicolaus set a $25.00 price target on Fulcrum Therapeutics in a research note on Monday, December 8th. Leerink Partners set a $20.00 price objective on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Truist Financial lifted their price objective on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Bank of America increased their target price on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research note on Tuesday, December 9th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $19.11.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.